Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - ENDRA Life Sciences Inc. | ndra_8k.htm |
Exhibit 99.1
ENDRA
Life Sciences Announces Separation of Units Sold in
IPO
Common Stock and Warrants to Trade Separately on The NASDAQ Capital
Market Beginning June 28, 2017
ANN ARBOR, Michigan - June 22, 2017 - ENDRA Life Sciences Inc.
(“ENDRA”) (NASDAQ: NDRAU), a developer of enhanced
ultrasound technologies, has announced that the 1,932,000 units
issued in its underwritten initial public offering will separate in
accordance with their terms on June 28, 2017. Each unit consists of
one share of common stock, par value $0.0001 per share, and a
five-year warrant to purchase one share of common stock at an
initial exercise price of $6.25 per share.
At the
commencement of trading on June 28, 2017, the common stock and
warrants will trade separately on The NASDAQ Capital Market under
the symbols “NDRA” and “NDRAW,”
respectively. The units, which are currently trading under the
symbol "NDRAU," will no longer be listed on The NASDAQ Capital
Market following the separation.
This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About ENDRA Life Sciences Inc.
ENDRA
Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRAU) is a
developer of enhanced ultrasound technologies. ENDRA’s
Photo-Acoustic Nexus-128 system is currently used by leading global
medical researchers to screen and modify disease models with high
image quality and volume scanning speed. ENDRA's next generation
Thermo-Acoustic Enhanced UltraSound (“TAEUS”) will
enable clinicians to visualize human tissue composition, function
and temperature in ways previously possible only on CT & MRI --
at a fraction of the cost, and at the point-of-care. ENDRA's first
TAEUS application will focus on the quantification of fat in the
liver, for early detection and monitoring of Non-Alcoholic Fatty
Liver Disease, which affects over 1 billion people globally.
ENDRA’s goal is to bring new capabilities to ultrasound --
thereby broadening access to better healthcare. For more
information, please visit www.endrainc.com.
Forward-Looking Statements
All
statements in this release that are not based on historical fact
are "forward-looking statements." While management has based any
forward-looking statements included in this release on its current
expectations, the information on which such expectations were based
may change. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially
from those in the forward-looking statements, as a result of
various factors including those risks and uncertainties described
in the Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of our
recently filed Quarterly Report on Form 10-Q, which can be found on
the SEC's website at www.sec.gov. We urge you to consider those
risks and uncertainties in evaluating our forward-looking
statements. We caution readers not to place undue reliance upon any
such forward-looking statements, which speak only as of the date
made. Except as otherwise required by the federal securities laws,
we disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Company Contact:
David
Wells
Chief
Financial Officer
(734)
997-0464
investors@endrainc.com
www.endrainc.com
Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us